Chemical Genomics Center Renews Five Licenses LANCASTER, Calif.–Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. National Institutes of Health to renew its licenses for the Company’s best-in-class ClassPharmer™ software. Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “This renewal for ClassPharmer licenses testifies to the utility the Chemical Genomics unit at the NIH has found using this unique software in its research efforts. Our licenses to government agencies, which include the National Institutes of Health, National Cancer Institute, Environmental Protection Agency, and Food and Drug Administration in the U.S., as well as the Japanese equivalents of the EPA and FDA, are an important part of our business, as these agencies are seen as centers of excellence in their respective areas of research. Their selection of tools sets an example for other organizations that do similar research.” About Simulations Plus, Inc. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab™, which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factor